Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
September 07 2021 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
trial in Alzheimer's disease with top-line data expected by
mid-November 2021 and a growing pipeline of therapeutics for
degenerative diseases, announced that Casey Lynch, chief executive
officer, co-founder, and chair, and Chris Lowe, chief operating
officer and chief financial officer, will participate in a fireside
chat at H.C. Wainwright 23rd Annual Global Investment Conference
taking place virtually on Monday, September 13, 2021 at 7:00 a.m.
Eastern Time.
A webcast of the event will be accessible on the Investor
Calendar page under the News & Events heading of Cortexyme’s
investor website at ir.cortexyme.com. The webcast will be archived
at that location for 90 days.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying pivotal GAIN Trial in mild to
moderate Alzheimer's disease with top-line data expected by
mid-November 2021, in addition to growing a proprietary pipeline of
first-in-class small molecule therapeutics for Parkinson’s disease,
periodontitis, and other diseases with high unmet clinical need.
Cortexyme’s lead program targets a specific, infectious pathogen
called P. gingivalis found in the brain and other organs and tied
to degeneration and inflammation in humans and animal models. The
company’s causation evidence for Alzheimer’s disease and the
mechanism of its novel therapeutic has been independently
replicated and confirmed by multiple laboratories around the world,
as well as published in peer-reviewed scientific journals. To learn
more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme
on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210907005282/en/
Corporate Contact: Stacy Roughan Vice President,
Corporate Communications & Investor Relations Cortexyme, Inc.
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024